• 제목/요약/키워드: Protein drug delivery

검색결과 82건 처리시간 0.025초

생분해성 폴리락티드/글리콜리드 미립구를 이용한 재조합 소 성장호르몬(rBST)의 지속성주사제 설계 (Sustained Release Injectable of Recombinant Bovine Somatotropin in Biodegradable Poly(D,L-lactide-co-glyceride) Microspheres)

  • 전홍렬;이봉상;권도우;윤미경;전현주;신택환;최영욱
    • Journal of Pharmaceutical Investigation
    • /
    • 제32권3호
    • /
    • pp.199-207
    • /
    • 2002
  • In order to develop a sustained release formulation of bovine somatotropin (BST), which has been used to increase the body weight of oxen or the milk production of dairy cows, poly(D,L-lactide-co-glyceride)(PLGA) microspheres were made by W/O/W multiple emulsification method and solvent extraction method. Physical properties including particle size, drug entrapment, drug release, protein denaturation, and in vivo body weight increase in rats were characterized. The size of the microspheres was increased as the molecular weight of PLGA increased. When Span 65 and stearic acid during preparation were added, the size was decreased but the amount of surface protein was increased, resulting in a high loading efficiency, with fast release of BST from the microspheres. Aggregation or fragmentation of BST by SDS-PAGE during microsphere preparation and drug release study was not observed. Body weight of Sprague-Dawley's male rats was significantly increased after subcutaneous administrations of BST-loaded PLGA microspheres. There was a good correlation between in vivo weight gain and in vitro release rate of microspheres. PLGA microspheres with a high surface protein ratio could be a good candidate for the sustained delivery of BST.

siRNA Silencing EZH2 Reverses Cisplatin-resistance of Human Non-small Cell Lung and Gastric Cancer Cells

  • Zhou, Wen;Wang, Jian;Man, Wang-Ying;Zhang, Qing-Wei;Xu, Wen-Gui
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권6호
    • /
    • pp.2425-2430
    • /
    • 2015
  • Clinical resistance to chemotherapeutic agents is one of the major hindrances in the treatment of human cancers. EHZ2 is involved in drug resistance and is overexpressed in drug-resistant cancer cell lines. In this study, we investigated the effects of EHZ2 on cisplatin -resistance in A549/DDP and AGS/DDP cells. EHZ2 mRNA and protein were found to be significantly overexpressed in A549/DDP and AGS/DDP cells, compared to parental cells. EHZ2 siRNA successfully silenced EHZ2 mRNA and protein expression. Proliferation was inhibited and drug resistance to cisplatin was improved. Flow cytometry showed that silencing of EHZ2 arrested A549/DDP and AGS/DDP cells in the G0/G1 phase, increasing apoptosis, rh-123 fluorescence intensity and caspase-3/8 activities. Silencing of EHZ2 also significantly reduced the mRNA and protein expression levels of cyclin D1 and MDR1,while up-regulating p15, p21, p27 and miR-218 in A549/DPP cells. Furthermore, silencing of EHZ2 also significantly increased the expression level of tumor suppressor factor miR-218. We also found down-regulating EHZ2 expression increased methylation in A549/DDP and AGS/DDP cells. This study demonstrates that drug resistance can be effectively reversed in human cisplatin-resistant lung and gastric cancer cells through delivery of siRNAs targeting EHZ2.

단백질 약물 전달을 위한 마이크로/나노 입자의 전기분무 제조법 (Electrospraying of Micro/Nano Particles for Protein Drug Delivery)

  • 유지연;김민영;이종휘
    • 폴리머
    • /
    • 제31권3호
    • /
    • pp.215-220
    • /
    • 2007
  • 전기분무에서의 전기유체 역학적 힘에 의한 표면 에너지의 조절은 간단한 입자 크기 조절, 단분산성, 높은 회수율, 그리고 약한 가공조건과 같은 이점을 제공할 수 있다. 이러한 이점은 단백질 약물전달체 제조에 적절할 것으로 예상되어, 본 연구에서 전기분무법을 이용하여 단백질 약물의 나노포집을 시도하였다. 모델 단백질인 알부민을 단축 혹은 동축 전기분무로 가공하였고 키토산, 폴리카플로락톤(PCL), 폴리 (에틸렌 글리콜) (PEG) 등이 포집물질로 사용되었다. 효율을 최대로 높이기 위해 분무액의 전기전도도, 유속, 전기포텐셜 구배의 거리 등과 같은 가공변수들이 조사되었다. 키토산 시스템에서 입자크기에 대한 공정 변수의 영향은 유속이 늦어질수록, 노즐과 집적부 사이의 거리가 가까울수록 입자 크기가 감소하는 것을 알 수 있었다. PCL 시스템에서는 단축 전기분무의 경우 유속이 늦어질수록, 동축 전기분무의 경우 내부와 외부 물질의 유속비가 클수록 입자 크기가 증가하는 것을 확인할 수 있었다. 전기분무 노즐에서 생성된 초기 입자들은 좁은 입자 크기 분포를 보였으나, 그것들이 집적부에 도달했을 때 입자들이 응집되는 경향이 있었다. 이러한 전기분무법에서 PCL, PEG, 키토산을 사용한 알부민의 효과적인 나노 포집은 12 kV 이상에서 성공적으로 이루어졌다.

바이오 센서 및 랩온어칩

  • 박유근
    • 전자공학회지
    • /
    • 제31권1호
    • /
    • pp.58-72
    • /
    • 2004
  • Smart sensors and biochip technologies have received a great deal of attention in recent years not only because of the enormous potential markets in the healthcare expenditures but more importantly because of its great impact on the quality of human life in the future. Collaborative research among BT (Bio Technologies), IT (Information Technologies) and NT (Nano Technologies) will bring us a new paradigm of the healthcare services. Examples include disease prediction based on the genetic tests, personal medicines, point-of-care analysis, rapid and sensitive infectious disease diagnostics, environmental monitoring for chemical or biological warfares, intelligent drug delivery systems etc. In this report, recent accomplishment in the research area on biosensors, DNA chips, Protein Chips and Lab-on-a-chips are reviewed.

  • PDF

Non-Functionalized Water Soluble Carbon Nanotubes

  • ;최정일;임연민;김유나;김창준;강상수;남태현;강동우
    • 한국재료학회:학술대회논문집
    • /
    • 한국재료학회 2010년도 춘계학술발표대회
    • /
    • pp.43.2-43.2
    • /
    • 2010
  • Most of previous methods for the dispersions of carbon nanotube were achieved by various chemical functionalizations. In this study, however, we generated highly water dispersed carbon nanofibers by altering intrinsic materials property only, such as crystallinity of outer layers of carbons, without chemical treatment. Although most of chemical functionalization requires acidic treatment and may degrade their chemical functions by interacting with other molecules, suggested strategy demonstrated a simple but chemically non-degradable carbon nanotube for the application of various medical applications, such as drug delivery system and implant coatings.Furthermore, protein adsorption was increased by the reducing surface crystalinity since outer activated surface induced more adsorption of oxygen and eventually greater protein adsorption than pristine carbon nanofibers.

  • PDF

In-silico Studies of Boerhavia diffusa (Purnarnava) Phytoconstituents as ACE II Inhibitor: Strategies to Combat COVID-19 and Associated Diseases

  • Rahul Maurya;Thirupataiah Boini;Lakshminarayana Misro;Thulasi Radhakrishnan
    • Natural Product Sciences
    • /
    • 제29권2호
    • /
    • pp.104-112
    • /
    • 2023
  • COVID-19 caused a catastrophe in human health. People infected with COVID-19 also suffer from various clinical illnesses during and after the infection. The Boerhavia diffusa plant is well known for its antihypertensive activity. ACE-II inhibitors and calcium channel blockers are reported as mechanisms for the antihypertensive activity of B. diffusa phytoconstituents. Various studies have said ACE-II is the virus's binding site to attack host cells. COVID-19 treatment commonly employs a variety of synthetic antiviral and steroidal drugs. As a result, other clinical illnesses, such as hypertension and hyperglycemia, emerge as serious complications. Safe and effective drug delivery is a prime objective of the drug development process. COVID-19 is treated with various herbal treatments; however, they are not widely used due to their low potency. Many herbal plants and formulations are used to treat COVID-19 infection, in which B. diffusa is the most widely used plant. The current study relies on discovering active phytoconstituents with ACE-II inhibitory activity in the B. diffusa plant. As a result, it can be used as a treatment option for patients with COVID-19 and related diseases. Different phytoconstituents of the B. diffusa plant were selected from the reported literature. The activity of phytoconstituents against ACE-II proteins has been studied. Molecular docking and ligand-protein interaction computation tools are used in the in-silico experiment. Physicochemical, drug-likeness, water solubility, lipophilicity, and pharmacokinetic parameters are used to evaluate phytoconstituents. Liriodenine has the best drug-likeness, bioactivity, and binding score characteristics among the selected ligands. The in-silico study aims to find the therapeutic potential of B. diffusa phytoconstituents against ACE-II. Targeting ACE-II also shows an effect against SARS-CoV-2. It can serve as a rationale for designing a drug for patient infected with COVID-19 and associated diseases.

Gintonin facilitates brain delivery of donepezil, a therapeutic drug for Alzheimer disease, through lysophosphatidic acid 1/3 and vascular endothelial growth factor receptors

  • Choi, Sun-Hye;Lee, Na-Eun;Cho, Hee-Jung;Lee, Ra Mi;Rhim, Hyewhon;Kim, Hyoung-Chun;Han, Mun;Lee, Eun-Hee;Park, Juyoung;Kim, Jeong Nam;Kim, Byung Joo;Nah, Seung-Yeol
    • Journal of Ginseng Research
    • /
    • 제45권2호
    • /
    • pp.264-272
    • /
    • 2021
  • Background: Gintonin is a ginseng-derived exogenous G-protein-coupled lysophosphatidic acid (LPA) receptor ligand, which exhibits in vitro and in vivo functions against Alzheimer disease (AD) through lysophosphatidic acid 1/3 receptors. A recent study demonstrated that systemic treatment with gintonin enhances paracellular permeability of the blood-brain barrier (BBB) through the LPA1/3 receptor. However, little is known about whether gintonin can enhance brain delivery of donepezil (DPZ) (Aricept), which is a representative cognition-improving drug used in AD clinics. In the present study, we examined whether systemic administration of gintonin can stimulate brain delivery of DPZ. Methods: We administered gintonin and DPZ alone or coadministered gintonin with DPZ intravenously or orally to rats. Then we collected the cerebral spinal fluid (CSF) and serum and determined the DPZ concentration through liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Results: Intravenous, but not oral, coadministration of gintonin with DPZ increased the CSF concentration of DPZ in a concentration- and time-dependent manner. Gintonin-mediated enhancement of brain delivery of DPZ was blocked by Ki16425, a LPA1/3 receptor antagonist. Coadministration of vascular endothelial growth factor (VEGF) + gintonin with DPZ similarly increased CSF DPZ concentration. However, gintonin-mediated enhancement of brain delivery of DPZ was blocked by axitinip, a VEGF receptor antagonist. Mannitol, a BBB disrupting agent that increases the BBB permeability, enhanced gintonin-mediated enhancement of brain delivery of DPZ. Conclusions: We found that intravenous, but not oral, coadministration of gintonin facilitates brain delivery of DPZ from plasma via LPA1/3 and VEGF receptors. Gintonin is a potential candidate as a ginseng-derived novel agent for the brain delivery of DPZ for treatment of patients with AD.

Biological Synthesis of Alkyne-terminated Telechelic Recombinant Protein

  • Ayyadurai, Niraikulam;Kim, So-Yeon;Lee, Sun-Gu;Nagasundarapandian, Soundrarajan;Hasneen, Aleya;Paik, Hyun-Jong;An, Seong-Soo;Oh, Eu-Gene
    • Macromolecular Research
    • /
    • 제17권6호
    • /
    • pp.424-429
    • /
    • 2009
  • In this study, we demonstrate that the biological unnatural amino acid incorporation method can be utilized in vivo to synthesize an alkyne-terminated telechelic protein, Synthesis of terminally-functionalized polymers such as telechelic polymers is recognized to be important, since they can be employed usefully in many areas of biology and material science, such as drug delivery, colloidal dispersion, surface modification, and formation of polymer network. The introduction of alkyne groups into polymeric material is particularly interesting since the alkyne group can be a linker to combine other materials using click chemistry. To synthesize the telechelic recombinant protein, we attempted to incorporate the L-homopropargylglycine into the recombinant GroES fragment by expressing the recombinant gene encoding Met at the codons for both N- and C-terminals of the protein in the Met auxotrophic E. coli via Hpg supplementation. The Hpg incorporation rate was investigated and the incorporation was confirmed by MALDI-TOF analysis of the telcchelic recombinant protein.

Application of periostin peptide-decorated self-assembled protein cage nanoparticles for therapeutic angiogenesis

  • Kim, Ba Reun;Yoon, Jung Won;Choi, Hyukjun;Kim, Dasol;Kang, Sebyung;Kim, Jae Ho
    • BMB Reports
    • /
    • 제55권4호
    • /
    • pp.175-180
    • /
    • 2022
  • Peptides are gaining substantial attention as therapeutics for human diseases. However, they have limitations such as low bioavailability and poor pharmacokinetics. Periostin, a matricellular protein, can stimulate the repair of ischemic tissues by promoting angiogenesis. We have previously reported that a novel angiogenic peptide (amino acids 142-151) is responsible for the pro-angiogenic activity of periostin. To improve the in vivo delivery efficiency of periostin peptide (PP), we used proteins self-assembled into a hollow cage-like structure as a drug delivery nanoplatform in the present study. The periostin peptide was genetically inserted into lumazine synthase (isolated from Aquifex aeolicus) consisting of 60 identical subunits with an icosahedral capsid architecture. The periostin peptide-bearing lumazine synthase protein cage nanoparticle with 60 periostin peptides multivalently displayed was expressed in Escherichia coli and purified to homogeneity. Next, we examined angiogenic activities of this periostin peptide-bearing lumazine synthase protein cage nanoparticle. AaLS-periostin peptide (AaLS-PP), but not AaLS, promoted migration, proliferation, and tube formation of human endothelial colony-forming cells in vitro. Intramuscular injection of PP and AaLS-PP increased blood perfusion and attenuated severe limb loss in the ischemic hindlimb. However, AaLS did not increase blood perfusion or alleviate tissue necrosis. Moreover, in vivo administration of AaLS-PP, but not AaLS, stimulated angiogenesis in the ischemic hindlimb. These results suggest that AaLS is a highly useful nanoplatform for delivering pro-angiogenic peptides such as PP.